Chen Qiyu

Mr. Chen Qiyu, aged 48, is currently a non-executive Director and vice chairman of the Company. He joined the Company in January 2003, and had served as the chief Supervisor of the Company until May 2010. He has served as a non-executive Director of the Company since May 2010 and has been the vice chairman since November 2013. Mr. Chen has over 27 years of working experience. He obtained a bachelor’s degree in genetics from Fudan University in July 1993 and a master’s degree of advanced business administration from China Europe International Business School in September 2005. Mr. Chen was previously the chief financial officer, the board secretary, general manager, president and vice chairman of the board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (a company listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange, stock code: 02196 (H Share)/600196 (A Share)) (“Fosun Pharmaceutical”) from July 1998 to May 2010, and has been its director and chairman since May 2005 and June 2010, respectively. Mr. Chen has served as the vice president, co-president and co-chief executive officer of Fosun International Limited (a company listed on the Hong Kong Stock Exchange, stock code: 00656) since August 2010, and has served as its executive director since July 2015. He has served as the vice president and co-president of Shanghai Fosun High Technology (Group) Co., Ltd. (“Fosun High Technology”) since January 2011, and has served as its director since July 2015 and has served as its Chairman since November 2017. Mr. Chen has been a director of Beijing Sanyuan Food Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600429) since September 2015. Mr. Chen has served as a director of Shanghai Henlius Biotech, Inc. (a company listed on the Hong Kong Stock Exchange, stock code: 02696) (“Henlius”) since January 2013 and as chairman of the company’s board of directors since December 2018; served as a non-executive director of Babytree Group (a company listed on the Hong Kong Stock Exchange, stock code: 01761) since June 2018; and served as the co-chairman of New Frontier Health Corporation (a company listed on the New York Stock Exchange, stock code: NFH) since December 2019. Mr. Chen served as the supervisor, director as well as the director and general manager of Sinopharm Investment from July 2008 to March 2014 successively, and has served as the vice chairman of the same since March 2014 till now. Mr. Chen is currently also the chairman of China Medical Pharmaceutical Material Association, vice chairman of China Association for Pharmaceutical Innovation, honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, the vice-chief of Shanghai Society of Genetics and the standing member of the 13th Shanghai Committee of the Chinese People’s Political Consultative Conference.